Stablecoin Development Corp. (SDEV) intrinsic value & 10-year financials

Stablecoin Development Corp. (SDEV) has no Graham intrinsic value right now because the formula needs positive earnings.

Graham intrinsic value
—
Share price (Oct 17, 2026)
$0.88
Market cap
$30.9M
Revenue (FY2025)
—
Revenue growth (10-yr CAGR)
-2.4%
ROIC (10-yr avg)
-161.2%
Free cash flow (FY2025)
—

SDEV 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 — -$22.1M — — — 55.9%
FY2024 $9.8M -$7.2M — -$7.5M -59.7% -601.3%
FY2023 $14.7M -$9.6M — -$4.2M -51.6% -188.2%
FY2022 $14.4M -$10.6M — -$6.8M -100.1% -297.5%
FY2021 $8.4M -$5.8M — -$9.2M -105.2% -526.6%
FY2020 $9.9M -$11.0M -$0.31 -$4.7M -64.7% 256.7%
FY2019 $6.6M -$9.7M -$0.48 -$7.9M -142.4% 172.2%
FY2018 $12.5M -$6.5M -$0.46 -$5.6M -62.9% —
FY2017 $18.2M -$7.4M -$0.48 -$6.5M -40.1% —
FY2016 $11.9M -$13.2M -$1.40 -$12.3M -92.3% —

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

Stablecoin Development Corp revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.

Stablecoin Development Corp has historically struggled to out-earn its cost of capital, averaging just 6.3% ROIC.

Stablecoin Development Corp capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.

Benjamin Graham lens

Under Benjamin Graham's formula using SEC EDGAR fundamentals, Stablecoin Development Corp is modeled at -2.4% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-1.99 per share.

SDEV stock: frequently asked questions

What is SDEV's return on invested capital?

Average ROIC over the last 10 fiscal years was -161.2%, and average return on equity was -156.0%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this SDEV data come from?

From Stablecoin Development Corp.'s annual 10-K filings on SEC EDGAR, most recently filed Jul 30, 2026. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar pharmaceutical preparations stocks